HQL News and Press, TeklaLife Sciences Investors From 12/21/20

On December 21, 2020, Tekla Life Sciences Investors declared a special cash distribution of $0.02 per share in order to satisfy annual tax distribution requirements. The record date for the distribution is December 31, 2020 and the payable date is January 6, 2021. The Fund will trade ex...

23 out of 23 CEF sectors positive on price and 22 out of 23 sectors positive on NAV last week. Rally continues for the fifth week; MLPs lead again. DSL cuts distribution. For further details see: Weekly Closed-End Fund Roundup: December 6, 2020

22 out of 23 CEF sectors positive on price and 21 out of 23 sectors positive on NAV last week. Rally continues for the fourth week as MLPs lead the way. DSL announces distribution cut, discussed in a separate report for members. For further details see: Weekly Closed-End...

21 out of 23 CEF sectors positive on price and 20 out of 23 sectors positive on NAV last week as rally continues for the third week. MLPs lead while real estate lags. Taxable munis are the most expensive CEF sector. For further details see: Weekly Closed-End Fund Roundup...

Tekla Life Sciences (HQL) declares $0.40/share quarterly dividend, -2.4% decrease from prior dividend of $0.41.Forward yield 8.69%Payable Dec. 31; for shareholders of record Nov. 27; ex-div Nov. 25.See HQL Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: ...

On November 16, 2020, Tekla Life Sciences Investors declared a distribution of $0.40 per share. The record date for the distribution is November 27, 2020 and the payable date is December 31, 2020. The Fund will trade ex-distribution on November 25, 2020. This distribution will autom...

HQH offers investors a quarterly distribution based on 2% of the NAV. Due to the fund's significant discount, the yield shareholders actually receive is even more attractive. The fund has also been a great performer due to the pandemic. For further details see: HQH: Deep...

Tekla Life Sciences (HQL) is a closed-end fund (CEF) managed by Tekla Capital Management; the fund invests in biotech industry stocks with up to 40% of the portfolio invested in pre-public (“venture”) companies, notes Tim Plaehn, editor of The Dividend Hunter. For further deta...

We analyze performance trends in closed-end-funds this year along with themes by asset classes. Equity funds with concentrated exposure to Technology and Healthcare are among the biggest winners this year. Energy focused funds have underperformed given the weaker pricing environme...

A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus. Firms are forging ahead with testing, treatment and vaccine research and product development. Results of even the most promising treatments, however, are not yet clear cut....